Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture.
Altered bone microstructure is a major component of osteoporosis and bone fragility. Whilst an important standard by which to diagnose and make treatment decisions for osteoporosis, the evaluation of bone mineral mass by dual-energy X-ray absorptiometry (DXA) at spine or hip is not sufficient for understanding the complex nature of bone microstructure nor to evaluate specific treatment effects on cancellous and cortical bone. Various alternatives to DXA have been developed, enabling the measurement of bone geometry and/or microarchitecture and/or bone strength including hip strength analysis, peripheral and central QCT, 3D analyses of iliac crest bone biopsies, and more recently HR-pQCT, which allows longitudinal assessment of bone microstructure at the distal radius and tibia. The efficacy of treatments for osteoporosis can be evaluated using these techniques. A true improvement of bone microstructure above baseline has not been demonstrated with anti-resorptive treatments; however, they may prevent the decay of cancellous bone and, potentially, cortical thinning. Anabolic agents such as parathyroid hormone (PTH) increase cancellous bone volume and cortical thickness; however, the improvement of cortical bone strength by PTH may be limited by an increase in cortical porosity. Strontium ranelate has been shown to improve not only the trabecular network but also cortical thickness, contributing to its anti-fracture efficacy at vertebral, non-vertebral, and hip sites.
Ferrari
S
S
Service of Bone Diseases, Geneva University Hospital (HUG), 24 rue Micheli-du-Crest, 1211, Geneva, Switzerland. serge.ferrari@medecine.unige.ch
D000368:Aged; D001706:Biopsy; D050071:Bone Density Conservation Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013876:Thiophenes / Q000494:pharmacology* / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate
Osteoporos Int. 2004 Feb;15(2):103-7
14605802
J Bone Miner Res. 2008 Apr;23(4):463-74
18052756
Osteoporos Int. 2008 Apr;19(4):399-428
18266020
J Bone Miner Res. 2001 Oct;16(10):1846-53
11585349
Bone. 2004 Apr;34(4):736-46
15050906
J Bone Miner Res. 2007 Jan;22(1):149-57
17042738
J Bone Miner Res. 2006 Jan;21(1):124-31
16355281
J Bone Miner Res. 2005 Sep;20(9):1548-61
16059627
Bone. 2009 Mar;44(3):413-7
19071239
J Bone Miner Res. 2003 Nov;18(11):1932-41
14606504
Calcif Tissue Int. 2003 Nov;73(5):423-32
12964065
Lancet. 2002 May 25;359(9320):1841-50
12044392
Bone. 2002 Nov;31(5):620-5
12477578
J Bone Miner Res. 2010 Mar;25(3):472-81
19778182
Bone. 2005 Jun;36(6):948-58
15878318
J Clin Invest. 1997 Sep 15;100(6):1475-80
9294113
J Bone Miner Res. 2008 Jan;23(1):6-16
17892374
J Bone Miner Res. 2009 Apr;24(4):737-43
19113929
Best Pract Res Clin Rheumatol. 2009 Dec;23(6):741-53
19945686
J Clin Endocrinol Metab. 2008 Jul;93(7):2594-601
18430772
J Bone Miner Res. 2007 Mar;22(3):425-33
17181395
J Bone Miner Res. 2008 Feb;23(2):205-14
17937534
Curr Med Res Opin. 2005 Feb;21(2):185-94
15801989
J Bone Miner Res. 2008 Feb;23(2):215-22
17922612
J Bone Miner Res. 2008 May;23(5):730-40
18251704
Osteoporos Int. 2010 Feb;21(2):263-73
19455271
Osteoporos Int. 2009 Jun;20(6):911-21
18830555
Osteoporos Int. 2009 Oct;20(10):1683-94
19152051
J Bone Miner Res. 2009 Aug;24(8):1358-68
19338452
J Bone Miner Res. 2009 Mar;24(3):468-74
19016592
J Bone Miner Res. 2007 Dec;22(12):1885-92
17680721
J Clin Endocrinol Metab. 2005 Dec;90(12):6508-15
16189253